Clinical Trials on Transition in New Zealand

Total 184 results

University of Rochester
Academic Pediatric Association

Completed

Adolescent to Adult-Oriented Health Care Transition Survey: Study of a Video-Based Educational Intervention

Transition to Adult Health Care

United States
NYU Langone Health

Completed

Testing the Efficacy of a Post-discharge Call Program on the Rate of Readmission

Care Transitions

United States
Trans Tasman Radiation Oncology Group
National Health and Medical Research Council, Australia

Completed

Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.

Transitional Cell Carcinoma of Urinary Bladder

Australia, New Zealand
Memorial Sloan Kettering Cancer Center
Novartis

Completed

Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium

Metastatic Transitional Cell Carcinoma of the Urothelium

United States
Rutgers University
Kessler Institute for Rehabilitation

Completed

KT Intervention to Increase Use of Outcome Measures

Knowledge Translation

United States
Yale University

Withdrawn

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

Transitional Cell Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals

Completed

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium

Bladder Cancer | Metastatic Transitional Cell Carcinoma

United States
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

Transitional Cell Carcinoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States
Tulane University Health Sciences Center

Completed

Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States
Endo Pharmaceuticals

Terminated

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Carcinoma in Situ | Transitional Cell Carcinoma | Non-muscle Invasive Bladder Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Pfizer

Completed

Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
UroGen Pharma Ltd.

Completed

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus)

Carcinoma, Transitional Cell | Transitional Cell Carcinoma of Renal Pelvis

United States, Israel
University of Rochester
National Institute on Aging (NIA)

Completed

CAPABLE Transitions: A Home Health-Based Intervention for the Hospital or Post-Acute Care Facility-to-Home Transition

Dementia | Care Transitions

United States
Memorial Sloan Kettering Cancer Center

Completed

Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging

Transitional Cell Carcinoma | Bladder Cancer

United States
Roswell Park Cancer Institute
Johns Hopkins University; National Cancer Institute (NCI)

Terminated

Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery

Recurrent Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer

United States
Weill Medical College of Cornell University
NeoTX Therapeutics Ltd.

Withdrawn

Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

Urothelial Carcinoma

United States
Medical Research Council

Completed

Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

Canada, United Kingdom, Norway, New Zealand, Netherlands, South Africa, Brazil, Finland
Northern Sydney and Central Coast Area Health Service

Enrolling by invitation

Transition of Care in Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus | Transition

Australia
Memorial Sloan Kettering Cancer Center
Astellas Pharma US, Inc.

Recruiting

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

Urothelial Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Mayo Clinic; Hartford Hospital

Active, not recruiting

Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

United States
Yale University
National Institute on Aging (NIA); Emergency Medicine Foundation; West Health...

Recruiting

Artificial Intelligence + Care Coach Intervention

Dementia | Artificial Intelligence | Emergency Department | Caregiver | Care Transition

United States
All India Institute of Medical Sciences, New Delhi

Completed

Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial

Renal Cell Carcinoma | Transitional Cell Carcinoma | AML | Renal Cysts

India
Pacific Edge Limited

Completed

The Cxbladder Monitoring Study

Urothelial Carcinoma

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)

Upper Tract Urothelial Carcinoma

United States
Steba Biotech S.A.
PrimeVigilance; ICON plc

Recruiting

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (UCM301)

Transitional Cell Cancer of Renal Pelvis and Ureter

United States, Israel, Spain, Italy, France, Germany, Austria
Amgen

Unknown

Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States
Cadila Pharnmaceuticals

Completed

Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder (STCC)

Bladder Cancer

India
Cadila Pharnmaceuticals

Completed

Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder (STCC)

Bladder Cancer

India
Genta Incorporated

Unknown

Tesetaxel for Previously Treated Patients With Bladder Cancer

Carcinoma, Transitional Cell

United States, Italy
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline

Terminated

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Bladder Cancer

United States
Arjun Balar, MD
Hoosier Cancer Research Network; Roche-Genentech

Terminated

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

Urothelial Carcinoma

United States
Memorial Sloan Kettering Cancer Center
University of Chicago; Genentech, Inc.; Ohio State University; Targos

Active, not recruiting

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Urothelial Carcinoma | Locally Advanced | Unresectable

United States
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC; Astellas Pharma US, Inc.; Seagen Inc.

Recruiting

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Urothelial Carcinoma

United States
Genentech, Inc.

Approved for marketing

An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

Urothelial Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Bayer

Terminated

Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Bladder Cancer | URINARY BLADDER

United States
Hoosier Cancer Research Network
Bristol-Myers Squibb

Completed

First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

Urothelial Carcinoma

United States
Genentech, Inc.

Terminated

A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy

Urothelial Carcinoma

Korea, Republic of, United States, Canada, United Kingdom, Belgium
Memorial Sloan Kettering Cancer Center

Completed

Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma

Cancer | Urothelial Carcinoma | Myeloproliferative Disorder

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Nabil Adra
Genentech, Inc.; Indiana University School of Medicine

Terminated

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Urothelial Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
Vyriad, Inc.
Mayo Clinic

Completed

Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy

Urothelial Carcinoma

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Five Prime Therapeutics, Inc.

Completed

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Gastric Cancer | Advanced Solid Tumors | Transitional Cell Carcinoma of the Bladder

Korea, Republic of, United States, Taiwan
Matthew Galsky
Novartis Pharmaceuticals; Hoosier Cancer Research Network

Terminated

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Transitional Cell Carcinoma | Urothelial Carcinoma | Bladder Carcinoma

United States
Matthew Galsky
AstraZeneca

Active, not recruiting

Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer

Urothelial Carcinoma

United States
MedPacto, Inc.
AstraZeneca

Not yet recruiting

Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Urothelial Carcinoma Recurrent | Advanced Urothelial Carcinoma

United States

Clinical Trials on Transition in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations